经皮导管置入急性腹膜透析治疗重症监护中COVID-19相关急性肾损伤:英国三级中心经验
该研究描述了在ICU中为COVID-19相关急性肾损伤患者经皮置入腹膜透析导管并立即开始腹膜透析的经验。44例患者中37例(84.1%)成功置管,中位ICU住院13.5天后置管,无不良事件,SOFA评分和通气需求置管前后相当,腹膜透析提供中位94.6%的肾脏替代治疗。结论认为对于选择性需通气的COVID-19合并AKI患者,腹膜透析是安全有效的CRRT替代方案。
要点
- 经皮置管后立即开始腹膜透析在ICU中可行,37/44例(84.1%)成功。
- 置管前后SOFA评分和通气需求无变化,无不良事件报告。
- 腹膜透析提供了中位94.6%的肾脏替代治疗,参数达标。
核心结论
- 对于选择性需通气的COVID-19合并AKI的ICU患者,腹膜透析是安全有效的CRRT替代方案。
研究设计与样本
- 单中心回顾性描述性研究,纳入44例COVID-19合并AKI的ICU患者,按本地方案选择并经皮Seldinger技术置管。
- 记录置管时和24小时后SOFA评分及通气需求,评估操作并发症、PD提供的RRT比例、肾功能恢复及RRT参数。
主要发现
- 44例中37例(84.1%)成功经皮置入PD导管,置管前中位ICU住院13.5天(IQR 10.0-20.3天)。
- 无不良事件报告,置管前后SOFA评分和通气需求相当,RRT参数达标。
- 置管后PD提供的中位RRT比例为94.6%(IQR 75.0-100%)。
临床怎么用
- 在ICU中,对选择性需通气的COVID-19合并AKI患者,可考虑经皮置管后立即开始腹膜透析作为CRRT的替代。
- 置管应由经验丰富的操作者采用Seldinger技术进行,并监测SOFA评分和通气需求变化。
局限性
- 单中心经验,样本量有限(44例),为描述性研究,未设对照组。
- 患者选择基于本地方案,结果可能受选择偏倚影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: During the coronavirus disease 2019 (COVID-19) pandemic in 2020, high rates of acute kidney injury (AKI) in critically unwell patients are being reported, leading to an increased demand for renal replacement therapy (RRT). Providing RRT for this large number of patients is proving challenging, and so alternatives to continuous renal replacement therapies (CRRT) in the intensive care unit (ICU) are needed. Peritoneal dialysis (PD) can be initiated immediately after percutaneous insertion of the catheter, but there are concerns about impact on ventilation and RRT efficacy. We sought to describe our recent experience with percutaneous catheter insertion and peritoneal dialysis in patients in the ICU with COVID-19 infection. METHOD: Patients were selected according to local protocol, and catheters were inserted percutaneously by experienced operators using a Seldinger technique. Sequential Organ Failure Assessment (SOFA) score and ventilation requirements were recorded at the time of insertion and 24 hours later. Procedural complications, proportion of RRT provided by PD, renal recovery, and RRT parameters (serum potassium and maximum base excess) during PD were assessed. RESULTS: Percutaneous PD catheters were successfully inserted in 37 of 44 patients (84.1%) after a median of 13.5 days (interquartile range [IQR] = 10.0, 20.3 days) in the ICU. No adverse events were reported; SOFA scores and ventilation requirements were comparable before and after insertion; and adequate RRT parameters were achieved. The median proportion of RRT provided by PD following catheter insertion was 94.6% (IQR = 75.0, 100%). CONCLUSION: Peritoneal dialysis provides a safe and effective alternative to CRRT in selected patients with AKI and COVID-19 infection requiring ventilation on intensive care.
引用
- Bowes E, Joslin J, Braide-Azikiwe DCB, et al. Acute Peritoneal Dialysis With Percutaneous Catheter Insertion for COVID-19-Associated Acute Kidney Injury in Intensive Care: Experience From a UK Tertiary Center. Kidney Int Rep. 2020. PMID: 33521400. doi:10.1016/j.ekir.2020.11.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。